Jeremy Basset-Sagarminaga
Jeremy Basset-Sagarminaga has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Ohad Cohen
Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Israel
4 shared publications Benedikt Voelker
MiniMed Tolochenaz Switzerland
2 shared publications- Javier Castañeda
Medtronic Bakken Research Center Maastricht The Netherlands
2 shared publications Tim Van Den Heuvel
Medtronic Diabetes Medtronic International Trading Sàrl Tolochenaz Switzerland
2 shared publications- Amelia Caretto
Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
1 shared publication Andrea Laurenzi
IRCCS San Raffaele Hospital Medicine and Diabetes Unit Milan Italy
1 shared publication
Latest Publications
- 3 May 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 6431-6434
Automated Insulin Delivery Maintains Stable Glycemic Control Across Seasons: Real‐World Data From Italy on 4801 Users
- 3 May 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 6431-6434
Automated Insulin Delivery Maintains Stable Glycemic Control Across Seasons: Real‐World Data From Italy on 4801 Users
- Open Access
- 19 October 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (S1) , 49-60
Safety and glycaemic control during exercise with the MiniMed™ 780G : A narrative review of evidence from lab to real world
Physical activity plays a critical role in reducing cardiovascular risk among individuals with type 1 diabetes (PwT1D); however, more than two‐thirds of PwT1D remain insufficiently active, primarily due to the unpredictability of glucose fluctuations and the fear of hypoglycaemia during exercise. Automated insulin delivery systems, such as the MiniMed™ 780G (MM780G), offer potential solutions by automating insulin dosing, supporting stable glucose control, and allowing for a higher temporary glucose target. This narrative review summarizes the current evidence on the safety and efficacy of the MM780G system during exercise in PwT1D, with a focus on the temporary target (TT) feature and real‐world usability. The MM780G consistently supports glycaemic safety during exercise, especially moderate‐intensity aerobic activity, with time in range frequently meeting or exceeding consensus guidelines. Activation of the TT feature 60‐ to 120‐min pre‐exercise, particularly when paired with reduced meal boluses, significantly lowers the risk of hypoglycaemia. Real‐world studies confirm its safety across varied activities, including prolonged aerobic exercise and contact sports. While evidence for resistance and high‐intensity exercise remains limited, initial findings are favourable. User education is crucial to optimize use, particularly in competitive and prolonged settings. The MM780G is a safe and effective tool for glycaemic management during exercise in PwT1D. Best outcomes are achieved through strategic use of the TT feature and meal bolus reduction, individualized carbohydrate strategies and proper education. Applying easy‐to‐follow pre‐exercising recommendations may encourage better engagement with regular exercising. Further research is needed on long‐term adaptations to training and resistance‐based exercise protocols.
- 19 October 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (S1) , 49-60
Open AccessSafety and glycaemic control during exercise with the MiniMed™ 780G : A narrative review of evidence from lab to real world
Physical activity plays a critical role in reducing cardiovascular risk among individuals with type 1 diabetes (PwT1D); however, more than two‐thirds of PwT1D remain insufficiently active, primarily due to the unpredictability of glucose fluctuations and the fear of hypoglycaemia during exercise. Automated insulin delivery systems, such as the MiniMed™ 780G (MM780G), offer potential solutions by automating insulin dosing, supporting stable glucose control, and allowing for a higher temporary glucose target. This narrative review summarizes the current evidence on the safety and efficacy of the MM780G system during exercise in PwT1D, with a focus on the temporary target (TT) feature and real‐world usability. The MM780G consistently supports glycaemic safety during exercise, especially moderate‐intensity aerobic activity, with time in range frequently meeting or exceeding consensus guidelines. Activation of the TT feature 60‐ to 120‐min pre‐exercise, particularly when paired with reduced meal boluses, significantly lowers the risk of hypoglycaemia. Real‐world studies confirm its safety across varied activities, including prolonged aerobic exercise and contact sports. While evidence for resistance and high‐intensity exercise remains limited, initial findings are favourable. User education is crucial to optimize use, particularly in competitive and prolonged settings. The MM780G is a safe and effective tool for glycaemic management during exercise in PwT1D. Best outcomes are achieved through strategic use of the TT feature and meal bolus reduction, individualized carbohydrate strategies and proper education. Applying easy‐to‐follow pre‐exercising recommendations may encourage better engagement with regular exercising. Further research is needed on long‐term adaptations to training and resistance‐based exercise protocols.
- 5 June 2025
- Published by Springer Nature in Acta Diabetologica
- Vol. 62 (11) , 1953-1957
Use of the temporary glycemic target feature in the medtronic MiniMed™ 780G advanced hybrid closed loop system: a real-world evidence study
Aim The MiniMed™ 780G system utilizes an Advanced Hybrid Closed-Loop algorithm, which is optimized to perform best at a glucose target of 100 mg/dL. The system also includes a temporary target feature (TT) of 150 mg/dL that can be set when higher glucose utilization is anticipated (e.g., exercise/strenuous work). Methods Real-world data from 1002 randomly selected users of the MiniMed™ 780G and MiniMed™ 670G systems were used to investigate the TT functionality (n = 501 MiniMed™ 780G users, n = 501 MiniMed™ 670G users). Continuous glucose monitoring (CGM) metrics were calculated for 4-h intervals (4 h prior to commencing TT use and 0–4, 4–8, 8–12, 12–16, 16–20 and 20–24 h after TT initiation). Results CGM results showed that, with both systems, the time-in-range (TIR) during TT periods mostly equalled or exceeded TIR in corresponding non-TT periods. In the first 4 h after TT initiation, the MiniMed™ 780G system demonstrated a TIR and time in tight range (TITR) of 71.6% and 46.4%, respectively, [a 1.6 (p = 0.11) and 2.6 (p = 0.009) percentage point benefit in TIR and TITR, respectively, versus the 670G system]. Mean time-below-range remained below target in both periods. Conclusions These findings confirm that the TT setting performs as intended, allowing users to maintain TIR during strenuous activity without compromising safety.
- 5 June 2025
- Published by Springer Nature in Acta Diabetologica
- Vol. 62 (11) , 1953-1957
Use of the temporary glycemic target feature in the medtronic MiniMed™ 780G advanced hybrid closed loop system: a real-world evidence study
Aim The MiniMed™ 780G system utilizes an Advanced Hybrid Closed-Loop algorithm, which is optimized to perform best at a glucose target of 100 mg/dL. The system also includes a temporary target feature (TT) of 150 mg/dL that can be set when higher glucose utilization is anticipated (e.g., exercise/strenuous work). Methods Real-world data from 1002 randomly selected users of the MiniMed™ 780G and MiniMed™ 670G systems were used to investigate the TT functionality (n = 501 MiniMed™ 780G users, n = 501 MiniMed™ 670G users). Continuous glucose monitoring (CGM) metrics were calculated for 4-h intervals (4 h prior to commencing TT use and 0–4, 4–8, 8–12, 12–16, 16–20 and 20–24 h after TT initiation). Results CGM results showed that, with both systems, the time-in-range (TIR) during TT periods mostly equalled or exceeded TIR in corresponding non-TT periods. In the first 4 h after TT initiation, the MiniMed™ 780G system demonstrated a TIR and time in tight range (TITR) of 71.6% and 46.4%, respectively, [a 1.6 (p = 0.11) and 2.6 (p = 0.009) percentage point benefit in TIR and TITR, respectively, versus the 670G system]. Mean time-below-range remained below target in both periods. Conclusions These findings confirm that the TT setting performs as intended, allowing users to maintain TIR during strenuous activity without compromising safety.
- Open Access
- 29 May 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 225, 112288
Hepatic steatosis is associated with impaired hepatic glucose uptake under hyperglycemic conditions, a dynamic whole-body 18F-FDG PET approach
- 29 May 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 225, 112288
Open AccessHepatic steatosis is associated with impaired hepatic glucose uptake under hyperglycemic conditions, a dynamic whole-body 18F-FDG PET approach
- 12 March 2025
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (4) , 1302-1310
Performance of an Automated Insulin Delivery System in People Living With Type 2 Diabetes and Insulin Resistance: First Real-World Evidence in 26,427 Users
Background: Type 2 diabetes (T2D) is a phenotypically heterogeneous disease. The use of insulin is required in a significant portion of people with T2D, despite recent developments in antidiabetic medications. This study analyzes glycemic outcomes in automated insulin delivery (AID) users with T2D with different insulin requirements. Methods: This is a retrospective, real-world analysis including MiniMed 780G (MM780G) data uploaded to CareLink Personal (January 2020 to April 2024). Four cohorts were identified based on phenotypes of T2D: (A) users with total daily dose of insulin (TDD) ≥ 100 IU, (B) users with self-reported T2D, (C) users with self-reported T2D and TDD ≥ 100 IU, and (D) users with self-reported T2D and TDD <100 IU. Glycemic outcomes and insulin use were assessed post-AID, pre-AID versus post-AID, and six-month longitudinal post-AID. Results: A total of 26 427 users were included in this study, of which 18 466 in cohort A, 10 795 in cohort B, 2 834 in cohort C, and 7 961 in cohort D. Mean time in range (TIR) was 71.1% ± 12.2 for cohort A, 75.1% ±14.1 for cohort B, 72.2% ± 15.0 for cohort C, and 76.1% ± 13.6 for cohort D. Mean time below range (TBR) <70 mg/dL was ≤1% in all cohorts. The users in cohort C using the recommended optimal settings (glucose target [GT] of 100 mg/dL and active insulin time [AIT] of two hours) had a greater TIR with 78.7% ± 10.8. All cohorts increased ≥10% post-AID compared with pre-AID. Conclusions: The use of this AID is associated with effective therapy outcomes, as indicated by over 70% TIR, and appears to be safe, as demonstrated by a low TBR in a large cohort of real-life users with self-reported T2D and high or low TDD.
- 12 March 2025
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (4) , 1302-1310
Performance of an Automated Insulin Delivery System in People Living With Type 2 Diabetes and Insulin Resistance: First Real-World Evidence in 26,427 Users
Background: Type 2 diabetes (T2D) is a phenotypically heterogeneous disease. The use of insulin is required in a significant portion of people with T2D, despite recent developments in antidiabetic medications. This study analyzes glycemic outcomes in automated insulin delivery (AID) users with T2D with different insulin requirements. Methods: This is a retrospective, real-world analysis including MiniMed 780G (MM780G) data uploaded to CareLink Personal (January 2020 to April 2024). Four cohorts were identified based on phenotypes of T2D: (A) users with total daily dose of insulin (TDD) ≥ 100 IU, (B) users with self-reported T2D, (C) users with self-reported T2D and TDD ≥ 100 IU, and (D) users with self-reported T2D and TDD <100 IU. Glycemic outcomes and insulin use were assessed post-AID, pre-AID versus post-AID, and six-month longitudinal post-AID. Results: A total of 26 427 users were included in this study, of which 18 466 in cohort A, 10 795 in cohort B, 2 834 in cohort C, and 7 961 in cohort D. Mean time in range (TIR) was 71.1% ± 12.2 for cohort A, 75.1% ±14.1 for cohort B, 72.2% ± 15.0 for cohort C, and 76.1% ± 13.6 for cohort D. Mean time below range (TBR) <70 mg/dL was ≤1% in all cohorts. The users in cohort C using the recommended optimal settings (glucose target [GT] of 100 mg/dL and active insulin time [AIT] of two hours) had a greater TIR with 78.7% ± 10.8. All cohorts increased ≥10% post-AID compared with pre-AID. Conclusions: The use of this AID is associated with effective therapy outcomes, as indicated by over 70% TIR, and appears to be safe, as demonstrated by a low TBR in a large cohort of real-life users with self-reported T2D and high or low TDD.